We are live on
!
Find out more
CIC
Cornercap Investment Counsel Portfolio holdings
AUM
$203M
1-Year Est. Return
17.67%
This Fund
S&P 500
This Quarter
Est. Return
+2.8%
1 Year Est. Return
+17.67%
3 Year Est. Return
+55.44%
5 Year Est. Return
+79.88%
10 Year Est. Return
+193.02%
AUM
$575M
AUM Growth
+$7.13M
(+1.3%)
Cap. Flow
-$3.73M
Cap. Flow
% of AUM
-0.65%
Top 10 Holdings %
Top 10 Hldgs %
8.61%
Holding
700
New
139
Increased
152
Reduced
171
Closed
133
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walt Disney
DIS
|
+$3M |
| 2 |
Paycom
PAYC
|
+$2.19M |
| 3 |
Salesforce
CRM
|
+$2.04M |
| 4 |
PPG Industries
PPG
|
+$2.01M |
| 5 |
Walmart Inc
WMT
|
+$1.99M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Wells Fargo
WFC
|
+$3.36M |
| 2 |
Comcast
CMCSA
|
+$3.32M |
| 3 |
AbbVie
ABBV
|
+$2.94M |
| 4 |
Amgen
AMGN
|
+$2.18M |
| 5 |
DFS
Discover Financial Services
DFS
|
+$1.94M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.22% |
| 2 | Financials | 16.95% |
| 3 | Healthcare | 13.98% |
| 4 | Industrials | 13.52% |
| 5 | Consumer Discretionary | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
First Horizon
FHN
$12.1B
| $169K | 0.03% |
14,973
| – | – |
|
527
Sutro Biopharma
STRO
$421M
| $168K | 0.03% |
3,616
+15
| +0.4% | +$747 |
|
528
Caribou Biosciences
CRBU
$164M
| $167K | 0.03% |
39,230
| – | – |
|
529
Annexon
ANNX
$886M
| $166K | 0.03% |
47,261
+2,204
| +5% | +$9.63K |
|
|
ITOS
530
DELISTED
iTeos Therapeutics
ITOS
| $166K | 0.03% |
12,557
| – | – |
|
531
Century Therapeutics
IPSC
$361M
| $165K | 0.03% |
52,175
| – | – |
|
532
Shattuck Labs
STTK
$694M
| $157K | 0.03% |
50,363
+361
| +0.7% | +$1.05K |
|
533
Erasca
ERAS
$6.39B
| $152K | 0.03% |
55,066
| – | – |
|
|
GRTS
534
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $152K | 0.03% |
77,848
+802
| +1% | +$1.88K |
|
535
Alector
ALEC
$199M
| $146K | 0.03% |
24,210
+519
| +2% | +$3.62K |
|
|
PSTX
536
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $143K | 0.02% |
80,979
+39,971
| +97% | +$102K |
|
537
CytomX Therapeutics
CTMX
$754M
| $142K | 0.02% |
82,415
| – | – |
|
|
NGM
538
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $134K | 0.02% |
51,721
+5,659
| +12% | +$20.2K |
|
539
C4 Therapeutics
CCCC
$412M
| $132K | 0.02% |
48,047
| – | – |
|
|
SGMO
540
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $117K | 0.02% |
90,265
+3,331
| +4% | +$4.55K |
|
541
Cartesian Therapeutics
RNAC
$268M
| $113K | 0.02% |
3,362
| – | – |
|
542
Adicet Bio
ACET
$74.7M
| $94K | 0.02% |
+2,418
| New | +$213K |
|
543
Nkarta
NKTX
$172M
| $85.8K | 0.01% |
39,196
| – | – |
|
544
Baytex Energy
BTE
$2.92B
| $81.1K | 0.01% |
+24,887
| New | +$87.1K |
|
|
KRON
545
DELISTED
Kronos Bio
KRON
| $70.2K | 0.01% |
40,788
+6,481
| +19% | +$10.3K |
|
546
Passage Bio
PASG
$14.1M
| $46.8K | 0.01% |
2,488
-2,586
| -51% | -$51.2K |
|
547
Q32 Bio
QTTB
$464M
| $33.5K | 0.01% |
2,104
-2,403
| -53% | -$43.1K |
|
|
ADAP
548
DELISTED
Adaptimmune Therapeutics
ADAP
| $12.2K | ﹤0.01% |
+13,166
| New | +$15.7K |
|
|
549
AbbVie
ABBV
$435B
| – | – |
-18,426
| Closed | -$2.94M |
|
|
ALEX
550
DELISTED
Alexander & Baldwin
ALEX
| – | – |
-40,605
| Closed | -$768K |
|
Similar funds
NWM
MAM
EECFX
PSB
HIA
NMG
EECFX
BC
Cornercap Investment Counsel's Q2 2023 Portfolio in Review
As of Q2 2023, Cornercap Investment Counsel held 700 positions worth $575M, up 1.3% from $568M the previous quarter. Its ten largest holdings account for 8.6% of the portfolio.
Cornercap Investment Counsel's Q2 2023 filing shows 139 new, 152 increased, 171 reduced and 133 closed positions. Its largest new stake was Walt Disney: 31,661 shares worth $2.83M. The largest sale was Wells Fargo, an estimated $3.36M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 16% a quarter earlier, followed by Financials and Healthcare.
- Cornercap Investment Counsel's largest Q2 2023 buy was Walt Disney: 31,661 shares worth $2.83M.
- Cornercap Investment Counsel added most to MSCI in Q2 2023, an estimated $1.63M increase.
- Cornercap Investment Counsel's biggest Q2 2023 reduction was Edwards Lifesciences, cutting an estimated $1.86M.
- Cornercap Investment Counsel fully exited Wells Fargo in Q2 2023, selling an estimated $3.36M.
- Cornercap Investment Counsel's ten largest holdings make up 8.6% of its $575M portfolio in Q2 2023.
- Cornercap Investment Counsel opened 139 new positions and closed 133 in Q2 2023.
- Cornercap Investment Counsel's portfolio value rose 1.3% quarter-over-quarter to $575M.
Based on Cornercap Investment Counsel's 13F filing for Q2 2023, filed 11 Aug 2023.